Real‐World Use of Dupilumab in Atopic Dermatitis: Observational Study Results Linked to SNDS
Fundamental & Clinical Pharmacology · 2026
DOI: 10.1111/fcp.70070 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Fundamental & Clinical Pharmacology, 2026. Verfasst von Alain Dupuy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Univ Rennes, CHU Rennes, Rennes, France. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Sanofi.
Abstract (Originalsprache)
Background
Dupilumab is reimbursed in France for adult patients with moderate‐to‐severe atopic dermatitis ( AD ), in cases of failure, intolerance or contraindication to cyclosporin A (CsA). The French National Authority for Health requested collection of data on dupilumab‐treated patients' characteristics and prior systemic treatments to examine conformity with the reimbursement scope.
Objectives
This study aimed to describe characteristics of adult patients initiating dupilumab for AD and their prior lines of systemic treatments with a focus on CsA.
Methods
Our dual approach combined information from two databases: the SNDS database allowing access to nationwide prescriptions for dupilumab (DUPIXAM study) and data collected by a sponsor‐initiated multicentre, cross‐sectional, observational study on patients initiating dupilumab for AD (MOVE study).
Results
From December 2019 to May 2021, 594 eligible patients were included in the MOVE study. In parallel, from March 2019 to December 2020, 3216 adult patients with presumed indications of moderate‐to‐severe AD were extracted from SNDS. Patients' characteristics were quite similar: median age was > 34 years old and they were gender balanced. More than 69% of MOVE patients had severe AD and 82.8% had at least one atopic comorbidities. Previous systemic treatments were used by over 62.8% of patients, of whom over 75.0% had received CsA. Among the 25.0% without previous CsA, the indirect combinatory approach made it possible to estimate an unbiased proportion of CsA contraindications in 71.0% of patients.
Conclusion
This joint analysis provided a detailed view of real‐world conditions of dupilumab use in France through the completeness of data, and constitutes a proof of concept that could be extended to address other health‐related questions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Univ Rennes, CHU Rennes, Rennes, France.
- Department of Dermatology, Hôpital d'Instruction des Armées Bégin Saint Mandé, Saint-Mandé, France.
- Department of Dermatology and Immunology Clinique Hôpital Privé d'Antony, Antony, France.
- Department of Dermatology, CHU Rennes, Rennes, France.
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Rennes, France.
- DAMAD SAS, Plouzané, France.
ORCID-Profile: Alain Dupuy, Catherine Droitcourt, Sandrine Kerbrat, Aymeric Mahieu, Jean-Philippe Lacour
Förderung
- Sanofi
Zitieren
APA
Dupuy, A., Fougerousse, A. C., Bécherel, P. A., Droitcourt, C., Kerbrat, S., Mahieu, A., Allali, N., Vataire, A. L., Thénié, C., Helman, N., & Lacour, J. P. (2026). Real‐World Use of Dupilumab in Atopic Dermatitis: Observational Study Results Linked to SNDS. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70070
Vancouver
Dupuy A, Fougerousse AC, Bécherel PA, Droitcourt C, Kerbrat S, Mahieu A, et al. Real‐World Use of Dupilumab in Atopic Dermatitis: Observational Study Results Linked to SNDS. Fundamental & Clinical Pharmacology. 2026. doi:10.1111/fcp.70070
BibTeX
@article{Dupuy2026,
author = {Dupuy, Alain and Fougerousse, Anne-Claire and Bécherel, Pierre-André and Droitcourt, Catherine and Kerbrat, Sandrine and Mahieu, Aymeric and Allali, Noémie and Vataire, Anne-Lise and Thénié, Claire and Helman, Nathalie and Lacour, Jean-Philippe},
title = {Real‐World Use of Dupilumab in Atopic Dermatitis: Observational Study Results Linked to SNDS},
journal = {Fundamental & Clinical Pharmacology},
year = {2026},
doi = {10.1111/fcp.70070}
}
EUVIMED